Shin Nippon Biomedical Laboratories, Ltd. (FRA:YB3)
Germany · Delayed Price · Currency is EUR 10.00
+0.50 (5.26%)
At close: Nov 28, 2025
FRA:YB3 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 34,671 | 32,413 | 26,450 | 25,090 | 17,748 | 15,110 | Upgrade | |
Revenue Growth (YoY) | 28.06% | 22.54% | 5.42% | 41.37% | 17.46% | 3.77% | Upgrade |
Cost of Revenue | 17,557 | 15,453 | 12,168 | 12,044 | 8,061 | 7,557 | Upgrade |
Gross Profit | 17,114 | 16,960 | 14,282 | 13,046 | 9,687 | 7,553 | Upgrade |
Selling, General & Admin | 11,247 | 11,062 | 8,116 | 6,830 | 4,908 | 4,482 | Upgrade |
Research & Development | 2,217 | 2,217 | 1,741 | 683 | 425 | 392 | Upgrade |
Operating Expenses | 14,160 | 13,975 | 10,120 | 7,801 | 5,491 | 5,024 | Upgrade |
Operating Income | 2,954 | 2,985 | 4,162 | 5,245 | 4,196 | 2,529 | Upgrade |
Interest Expense | -235 | -202 | -138 | -125 | -126 | -184 | Upgrade |
Interest & Investment Income | 159 | 98 | 188 | 58 | 8 | 2 | Upgrade |
Earnings From Equity Investments | 2,994 | 3,513 | 2,751 | 2,489 | 1,439 | 846 | Upgrade |
Currency Exchange Gain (Loss) | 113 | -162 | 60 | 1,511 | 1,370 | 239 | Upgrade |
Other Non Operating Income (Expenses) | 262 | 217 | -7 | 16 | 190 | 211 | Upgrade |
EBT Excluding Unusual Items | 6,247 | 6,449 | 7,016 | 9,194 | 7,077 | 3,643 | Upgrade |
Gain (Loss) on Sale of Investments | -152 | -131 | 51 | -1,327 | 1,381 | 1,173 | Upgrade |
Gain (Loss) on Sale of Assets | -226 | -228 | -50 | -13 | -21 | -4 | Upgrade |
Asset Writedown | -289 | -78 | -34 | -44 | -225 | -639 | Upgrade |
Other Unusual Items | - | - | -9 | -51 | -30 | - | Upgrade |
Pretax Income | 5,580 | 6,012 | 6,974 | 7,759 | 8,182 | 4,173 | Upgrade |
Income Tax Expense | 991 | 1,148 | 1,456 | 1,708 | 1,016 | 497 | Upgrade |
Earnings From Continuing Operations | 4,589 | 4,864 | 5,518 | 6,051 | 7,166 | 3,676 | Upgrade |
Minority Interest in Earnings | 65 | 60 | 13 | 9 | -39 | -15 | Upgrade |
Net Income | 4,654 | 4,924 | 5,531 | 6,060 | 7,127 | 3,661 | Upgrade |
Net Income to Common | 4,654 | 4,924 | 5,531 | 6,060 | 7,127 | 3,661 | Upgrade |
Net Income Growth | 19.46% | -10.97% | -8.73% | -14.97% | 94.67% | 43.57% | Upgrade |
Shares Outstanding (Basic) | 42 | 42 | 42 | 42 | 42 | 42 | Upgrade |
Shares Outstanding (Diluted) | 42 | 42 | 42 | 42 | 42 | 42 | Upgrade |
Shares Change (YoY) | - | - | - | -0.00% | - | - | Upgrade |
EPS (Basic) | 111.79 | 118.28 | 132.86 | 145.56 | 171.19 | 87.94 | Upgrade |
EPS (Diluted) | 111.79 | 118.28 | 132.86 | 145.56 | 171.19 | 87.94 | Upgrade |
EPS Growth | 19.46% | -10.97% | -8.73% | -14.97% | 94.67% | 43.57% | Upgrade |
Free Cash Flow | 2,178 | -3,818 | -6,476 | -834 | 4,410 | 3,679 | Upgrade |
Free Cash Flow Per Share | 52.32 | -91.71 | -155.56 | -20.03 | 105.93 | 88.37 | Upgrade |
Dividend Per Share | 50.000 | 50.000 | 50.000 | 50.000 | 30.000 | 10.000 | Upgrade |
Dividend Growth | - | - | - | 66.67% | 200.00% | 100.00% | Upgrade |
Gross Margin | 49.36% | 52.33% | 54.00% | 52.00% | 54.58% | 49.99% | Upgrade |
Operating Margin | 8.52% | 9.21% | 15.73% | 20.91% | 23.64% | 16.74% | Upgrade |
Profit Margin | 13.42% | 15.19% | 20.91% | 24.15% | 40.16% | 24.23% | Upgrade |
Free Cash Flow Margin | 6.28% | -11.78% | -24.48% | -3.32% | 24.85% | 24.35% | Upgrade |
EBITDA | 5,987 | 5,595 | 6,029 | 6,845 | 5,373 | 3,716 | Upgrade |
EBITDA Margin | 17.27% | 17.26% | 22.79% | 27.28% | 30.27% | 24.59% | Upgrade |
D&A For EBITDA | 3,033 | 2,610 | 1,867 | 1,600 | 1,177 | 1,187 | Upgrade |
EBIT | 2,954 | 2,985 | 4,162 | 5,245 | 4,196 | 2,529 | Upgrade |
EBIT Margin | 8.52% | 9.21% | 15.73% | 20.91% | 23.64% | 16.74% | Upgrade |
Effective Tax Rate | 17.76% | 19.10% | 20.88% | 22.01% | 12.42% | 11.91% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.